Sind das die 11Millionen Aktien,die SBI gerade für 2,9Millionen erworben hat von BIPH ,die sonst längst pleite wären,noch nie irgendwelche Umsätze gemacht haben und eine lange Geschichte von Verlusten haben?Und ihre Lizenz für MRI noch nicht mal an Biomed bezahlt haben,dessen Manager Michael L.Weiner gleichzeitig President und Ceo von Biophan ist...
www.pinksheets.com/quote/filings.jsp?symbol=BIPH Verkaufs-Filings vom 18.und 20.November,seit 20.November an der Börse Frankfurt gelistet
Auszug aus Filing:
we began our current line of business on December 1, 2000. From that date through our fiscal quarter ended August 31, 2003, we have had no revenues from operations and have incurred cumulative net losses of $9,328,746. Since December 1, 2000, we have relied entirely on sales of our securities and loans to fund our operations.
shares outstanding seit 2001 :38,532,599 31,731,051 27,000,962 9,166,887
As of October 31, 2003, we had 46,006,074 outstanding shares and outstanding options and warrants to purchase an additional 7,415,989 shares
SBI Brightline Consulting, LLC 11Millionen Shares Verkauf an SBI for an aggregate purchase price of $2.9 million
Working capital (deficiency) (784,883)
We Have A History Of Losses And A Large Accumulated Deficit
Companies such as Medtronic Incorporated, Guidant Corporation, St. Jude Medical, Boston Scientific and Johnson & Johnson are major, international providers of active medical devices currently contraindicated for MRI
Michael L. Weiner, our President, CEO and director, is the Manager and a 24.3% beneficial equity member of Biomed. Mr. Weiner, and Ross Kenzie, also a director of Biophan, make up the Biomed Board of Members. Biomed and its members own a significant amount of our outstanding common stock and we owe Biomed $500,000 plus interest for the transfer to us of its MRI-compatible pacemaker patents pending
Biomed is a creditor of Biophan and has the right to reacquire the MRI-compatible technology that it sold to us if payments are not made on a timely basis